A wider eligibility window than most patients expect

Most patients arrive expecting to be told they're either a candidate or they're not — that some threshold of age or joint damage rules them out. With ChondroFiller® injection, that framing rarely applies. The injection pathway is indicated for adults across the full range of cartilage wear: from a single contained chondral lesion to diffuse degeneration spanning multiple joint compartments. There is no upper age limit, and unlike surgical cartilage repair techniques, the injection pathway carries no defect-size ceiling.

Patients who come through most often include those with post-traumatic chondral lesions, osteochondritis dissecans (OCD), and cartilage damage that developed in the wake of a meniscal injury or ligament reconstruction. Active adults in their 60s and 70s who want to preserve the joint rather than replace it are explicitly within scope — not edge cases.

What the assessment does focus on is joint mechanics: cartilage damage that coexists with untreated ligament instability, significant malalignment, or ongoing meniscal deficit requires those issues to be addressed first, since ChondroFiller supports the body's own repair processes at the cartilage surface but does not correct the underlying mechanical environment.

How Kellgren-Lawrence grade shapes the treatment plan

The Kellgren-Lawrence (KL) scale grades osteoarthritis severity on plain X-ray from Grade I (subtle joint-space narrowing and early surface changes) to Grade IV (bone-on-bone contact with severe structural loss). In conventional surgical cartilage repair, Grade IV has long sat outside the treatable range. The ChondroFiller injection pathway inverts that assumption across every tier.

KL Grade I–II wear — early focal or mildly diffuse cartilage loss — is typically addressed with ChondroFiller injection alone. The acellular collagen scaffold coats the affected surface and promotes endogenous repair without requiring additional agents.

KL Grade III/IV advanced osteoarthritis calls for a different approach. The recommended protocol at this tier pairs ChondroFiller (2.3 mL) with Arthrosamid (6 mL) as a dual injection. These products are not interchangeable: ChondroFiller is the regenerative scaffold component, working at the cartilage surface on the load-bearing bone ends; Arthrosamid is a polyacrylamide hydrogel that integrates into the synovial lining to provide mechanical cushioning. Two products, two tissue targets, two distinct mechanisms — Arthrosamid has no role here as a standalone regenerative option.

For the most severely degraded KL Grade IV joints — historically considered unsuitable for anything short of joint replacement — the framework extends further still. Evidence from Weninger et al. (2025) supports combining the ChondroFiller scaffold with mesenchymal stem cell (MSC) co-delivery, a tri-active approach reserved for cases where viable tissue is most limited. This combined protocol has not yet been evaluated in a standalone randomised controlled trial, and suitability is determined case by case at clinical assessment. The fact that Grade IV represents an indication rather than an exclusion marks a genuine departure from the logic that governs most regenerative and surgical cartilage repair pathways.

Lesion size and the injection pathway's no-ceiling rule

Surgical cartilage repair options come with built-in size limits. Microfracture is generally reserved for defects below 2–4 cm²; ACI and MACI extend the ceiling to roughly 6 cm², but both demand a contained lesion with healthy surrounding borders and a prepared, dry surgical field. Patients with larger or more diffuse damage have historically been told that no repair technique can accommodate them.

The injection pathway works differently. ChondroFiller's collagen scaffold is placed under ultrasound guidance and gels in situ, coating worn articular surfaces in a fluid joint environment — no debridement required, no containment prerequisites. Because the scaffold is applied additively, layered over existing tissue rather than inserted into a prepared defect bed, lesion area does not become an exclusion criterion. Standard presentations are covered with a single box of product; larger surface areas or multi-compartment joints may need two or three boxes, with quantity determined by coverage area rather than disease severity grade alone.

ICRS grading — Grade 2 (cartilage loss to less than half the tissue depth) through Grade 4 (penetration to subchondral bone) — provides useful shorthand for the surgical route, where lesion dimensions and border integrity drive decision-making. For the injection pathway, ICRS classification is informative background rather than a candidacy screen. The relevant question is whether joint mechanics are stable; there is no published defect-size upper limit beyond which injection becomes inappropriate.

Prerequisites — joint stability and what must be corrected first

Broad eligibility does not mean unconditional eligibility. The one condition that consistently affects candidacy is an unstable joint — specifically, a joint whose mechanics are still actively driving damage at the time of assessment.

ChondroFiller's collagen scaffold integrates over weeks as the patient's own progenitor cells migrate into it. If abnormal load persists — because of untreated ligament laxity, significant varus or valgus malalignment, or a meniscal deficit creating uneven articular stress — the scaffold is working against ongoing wear rather than consolidating on a stable surface. That is not a basis for rejection; it is a basis for sequencing. Ligament reconstruction, osteotomy, or meniscal management may need to happen before, or concurrently with, the injection, depending on severity.

None of these factors constitutes an absolute exclusion. Most patients with some degree of instability or alignment change still qualify — the question a candidacy consultation explores is whether those mechanical contributors are significant enough to undermine scaffold integration, and if so, what the appropriate order of treatment is. The assessment that follows addresses precisely this: imaging, clinical examination, and load-pattern review together determine whether a patient is injection-ready now or benefits from a staged plan first.

What a candidacy assessment actually involves

The assessment is a clinical synthesis, not a scan-and-decide checklist. An MRI sent in advance of your appointment characterises defect morphology, tissue depth, and the health of surrounding cartilage and bone — all essential inputs — but it cannot tell your specialist whether your joint loads symmetrically, whether your knee tracks correctly under bodyweight, or how your symptoms pattern across a working day. Those answers come from clinical examination.

At consultation, the treating clinician works across several data streams simultaneously: weight-bearing X-ray provides the KL grade; MRI supplies ICRS depth classification and MOCART-style tissue context; and physical examination tests stability, alignment, and load response under real joint mechanics. Alongside these, your activity goals, previous treatment history, and tolerance of interventional procedures all inform the final pathway decision. The conversation is genuinely two-directional — a patient seeking to maintain recreational sport in their late sixties and one looking to manage daily pain in an arthritic thumb will arrive at different treatment tiers even with comparable imaging findings.

Patients with more complex presentations — multi-compartment wear, prior procedures, or alignment concerns — may need additional biomechanical review before a pathway is agreed. That is a quality standard, not a barrier. Published outcomes for ChondroFiller, including IKDC improvements of approximately 30 points at 12 months and MOCART scores of 70–87, reflect patients assessed through structured pre-injection evaluation — not those treated on the basis of imaging alone.

Taking the next step toward a candidacy decision

Confirming candidacy requires a structured appointment — imaging review and clinical examination together, not either alone. If you have a recent MRI, sharing it ahead of your consultation allows the specialist to map defect morphology before you arrive, making the appointment more focused and the pathway discussion more precise.

London Cartilage Clinic, based on Harley Street, offers specialist assessment for the ChondroFiller injection pathway across knee, hip, ankle, and upper-limb joints. Patients based further afield may find assessment more convenient through the wider MSK Doctors group's Lincolnshire and Grantham sites.

To explore whether ChondroFiller is suitable for your joint, book a consultation at londoncartilage.com.